>I would have thought the definition of a biosimilar would refer to the finished product, not to the process to arrive at the finished product.<
What defines a drug as a FoB or biosimilar is not the process to arrive at the finished product but rather the process to obtain regulatory approval. As stated in my prior post, if a drug obtains regulatory approval without relying, in whole or in part, on the clinical data of another drug, then it is not a FoB or biosimilar––it is simply a branded drug.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.